Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you prefer prescribing lubiprostone over conventional stool softeners in patients with CKD and constipation?
Sumida K, et al., PMID 40591438
Related Questions
Do you recommend temporarily holding SGLT2 inhibitors in patients with CKD who are undergoing CT imaging with intravenous contrast?
What is your approach to bisphosphonate use in patients with advanced chronic kidney disease and osteoporosis?
Would you avoid SGLT2 inhibitors in patients with urinary incontinence requiring incontinence briefs due to concern with genitourinary hygiene and risk for infections?
Do you recommend avoiding SGLT2i use for patients with proteinuria from diabetic kidney disease if they have urinary retention requiring catheterization?
Do you prioritize adding a GLP-1 receptor agonist over an SGLT-2 inhibitor in patients with CKD related to type 2 diabetes, uncontrolled proteinuria despite being on an ACEi, and obesity?
Would you recommend the use of an ACE inhibitor to patients with Type 1 diabetes mellitus who are normotensive but have persistent moderate proteinuria?
How do you tailor protein intake recommendations for older patients with stages 3-5 non-dialysis dependent CKD, considering the unique metabolic and physiologic factors that influence protein metabolism in this population?
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
Do you recommend patients with chronic kidney disease avoid supplements containing creatine?
What is your approach to managing constipation in patients with chronic kidney disease?
